S Percy Ivy

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1315450/publications.pdf

Version: 2024-02-01

27	2,782	471509	552781
papers	citations	17 h-index	26 g-index

27	27	27	5558
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Trends in Grade 5 Toxicity and Response in Phase I Trials in Hematologic Malignancy: 20-Year Experience From the Cancer Therapy Evaluation Program at the National Cancer Institute. Journal of Clinical Oncology, 2022, 40, 1949-1957.	1.6	4
2	The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study. Journal of the National Cancer Institute, 2021, 113, 27-37.	6.3	17
3	Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment. Cancer Cell, 2021, 39, 38-53.e7.	16.8	65
4	Outcomes of Pregnancy During Immunotherapy Treatment for Cancer: Analysis of Clinical Trials Sponsored by the National Cancer Institute. Oncologist, 2021, 26, e1883-e1886.	3.7	19
5	Quantitation of iohexol, a glomerular filtration marker, in human plasma by LCâ€“MS/MS. Journal of Pharmaceutical and Biomedical Analysis, 2020, 189, 113464.	2.8	4
6	Evaluation of the pharmacokinetic drug-drug interaction potential of iohexol, a renal filtration marker. Cancer Chemotherapy and Pharmacology, 2020, 86, 535-545.	2.3	3
7	Defining and targeting wild-type BRCA high-grade serous ovarian cancer: DNA repair and cell cycle checkpoints. Expert Opinion on Investigational Drugs, 2019, 28, 771-785.	4.1	9
8	Technology Applications: Use of Digital Health Technology to Enable Drug Development. JCO Clinical Cancer Informatics, 2018, 2, 1-12.	2.1	14
9	Drug development and registration: Challenges and opportunities in ovarian cancer. Cancer, 2017, 123, 2597-2599.	4.1	0
10	The HRD Decisionâ€”Which PARP Inhibitor to Use for Whom and When. Clinical Cancer Research, 2017, 23, 7155-7157.	7.0	22
11	Whence High-Grade Serous Ovarian Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 443-448.	3.8	15
12	Modernizing Clinical Trial Eligibility: Recommendations of the American Society of Clinical Oncologyâ€“Friends of Cancer Research Minimum Age Working Group. Journal of Clinical Oncology, 2017, 35, 3781-3787.	1.6	69
13	The â€˜Pushmi-Pullyuâ€™ of DNA REPAIR: Clinical Synthetic Lethality. Trends in Cancer, 2016, 2, 646-656.	7.4	18
14	Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer. Expert Opinion on Investigational Drugs, 2016, 25, 597-611.	4.1	44
15	Phase I Clinical Trials in Acute Myeloid Leukemia: 23-Year Experience From Cancer Therapy Evaluation Program of the National Cancer Institute. Journal of the National Cancer Institute, 2016, 108, .	6.3	7
16	Effect of Renal Dysfunction on Toxicity in Three Decades of Cancer Therapy Evaluation Programâ€“Sponsored Single-Agent Phase I Studies. Journal of Clinical Oncology, 2016, 34, 110-116.	1.6	27
17	CECs and IL-8 Have Prognostic and Predictive Utility in Patients with Recurrent Platinum-Sensitive Ovarian Cancer: Biomarker Correlates from the Randomized Phase-2 Trial of Olaparib and Cediranib Compared with Olaparib in Recurrent Platinum-Sensitive Ovarian Cancer. Frontiers in Oncology, 2015, 5, 123.	2.8	21
18	A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortia. Gynecologic Oncology, 2015, 137, 216-222.	1.4	65

#	Article	IF	Citations
19	Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update. Nature Reviews Clinical Oncology, 2015, 12, 445-464.	27.6	1,053
20	Predictors of early treatment discontinuation in patients enrolled on Phase I oncology trials. Oncotarget, 2015, 6, 19316-19327.	1.8	13
21	Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncology, The, 2014, 15, 1207-1214.	10.7	523
22	Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: Results of a DLT-TARGETT international survey. European Journal of Cancer, 2014, 50, 2050-2056.	2.8	63
23	A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors. Investigational New Drugs, 2013, 31, 1182-1191.	2.6	50
24	Approaches to Phase 1 Clinical Trial Design Focused on Safety, Efficiency, and Selected Patient Populations: A Report from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee. Clinical Cancer Research, 2010, 16, 1726-1736.	7.0	152
25	The Design of Phase II Clinical Trials Testing Cancer Therapeutics: Consensus Recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee. Clinical Cancer Research, 2010, 16, 1764-1769.	7.0	143
26	An overview of small-molecule inhibitors of VEGFR signaling. Nature Reviews Clinical Oncology, 2009, 6, 569-579.	27.6	305
27	Molecular Mechanism of Antifolate Transport-Deficiency in a Methotrexate-Resistant MOLT-3 Human Leukemia Cell Line. Blood, 1997, 89, 2494-2499.	1.4	57